Hanmi’s Epe Begins Prescriptions on the 29th
Hanmi’s Epe, described as Korea’s first domestically developed obesity drug, is set to begin prescriptions on the 29th.
Related stories
Avolta CFO Says EMEA Growth Is Supported by Central Europe and Mediterranean Markets
Avolta’s CFO said growth is being supported by markets outside the Middle East, particularly Central Europe and the Mediterranean area.
M impact | EQUITY | Oct 29, 2026, 02:42 PM UTC
Avolta CFO Says Growth Is Supported by Central Europe and Mediterranean Markets
Avolta’s CFO said growth in EMEA is being supported by markets outside the Middle East, particularly Central Europe and the Mediterranean area.
M impact | EQUITY | Oct 29, 2026, 02:42 PM UTC
Afaq Holding Reports Q3 Revenue of 17 Million Dinars
M impact | EQUITY | Oct 29, 2026, 02:42 PM UTC
Afaq Holding reports Q3 loss of 328,057 dinars
M impact | EQUITY | Oct 29, 2026, 02:41 PM UTC
Teladoc Health Reports Q3 Revenue of $605.1M, Loss Narrows
Third-quarter revenue fell 3.4% year over year to $605.1 million. Net loss narrowed to $26.93 million from $49.51 million, while diluted loss per share was $0.15 versus $0.28 a yea
M impact | EQUITY | Oct 29, 2026, 02:41 PM UTC
Klabin Sees El Niño Pressuring Operations Through Q1 2027
Klabin sees El Niño pressuring its operations through the first quarter of 2027.
L impact | EQUITY | Oct 29, 2026, 02:41 PM UTC